Three-person in-vitro fertilization sounds like something out of science fiction—or pulp fiction—but until recently it was the only known technique to prevent women who have damaging mitochondrial DNA mutations from passing on life-threatening disorders to their babies. And it is illegal in the U.S (clinical trials required by the FDA have not been completed). Now researchers at the University of Miami have demonstrated a new strategy that could one day treat these disorders both in adult carriers and in their already born children.
Later this fall, a few, a precious few, ASCB members will be booking flights to Stockholm. For the rest of us, take a seat with your laptop tonight to watch live as another batch of Nobelists—the Ig Nobelists—step into the bright lights. This is one show you will be glad to miss as an honoree.
At first glance, possible U.S. military action in far-off Syria may not seem to have implications for the American biomedical research community. However, any debate in Congress on whether to give President Obama authorization to launch military strikes on Syria could have significant impact on both research funding and immigration reform affecting the scientific workforce.
Today Richard H. Scheller, an ASCB member and Executive Vice President of Genentech, was named the winner, along with Thomas C. Südhof of Stanford University, of the 2013 Albert Lasker Basic Medical Research Award. They won for their separate work in understanding the regulatory mechanisms of neurotransmitter release.